Clinical Rheumatology

, Volume 28, Issue 2, pp 167–172 | Cite as

Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors

  • Inbal Fuchs
  • Lone Avnon
  • Tamar Freud
  • Mahmoud Abu-Shakra
Original Article

Abstract

To determine the rate of true tuberculin skin test (TST) response in a cohort of patients with rheumatic disease treated with tumor necrosis factor inhibitors (TNFi). The study population included consecutive patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) treated with TNFi for at least 3 months. Patients with a positive TST at screening who began Tb prophylaxis before the beginning of TNFi therapy were excluded. All patients underwent a second TST. True TST response was defined as an increase of 6 mm of induration between the screening test and the second test. Forty patients (12 men and 28 women) were included. Mean age was 51.2 years. Of them, 27 (67.5%) had RA, eight (20%) had PsA, and five patients (12.5%) had AS. At pre-treatment TST, 15 patients had a TST ≥ 5 mm. A significantly higher percent of patients with TST ≥ 5 mm was seen among men compared with women (75% vs. 21%, p = 0.012) and patients with PsA compared with patients with RA (75% vs. 22%, p = 0.014). At the second test, eight (20%) had an increase of 6 mm between readings with four having an increase of 10 mm or more. Four patients received infliximab and the other four were treated with etanercept. Seven of these eight patients had RA and one was a patient with PsA. Patients with true TST response were significantly older and non-smokers with elevated sedimentation rate and a higher rate of anemia. Nationality, comorbid conditions, treatment with immunosuppressives, and BCG vaccination status had no significant influence on the TST response. Serial TST testing in patients receiving TNFi is indicated to identify patients with reactivation of latent tuberculosis infection or those exposed to mycobacterium.

Keywords

Conversion TNF inhibitors Tuberculin 

Notes

Acknowledgement

The authors would like to thank Prof. Camil Fuchs for his help with statistical analysis and Ms. Maria Rubinstein and Ms. Ruthie Hadar for their help in conducting the skin tests.

Disclosures

None.

References

  1. 1.
    Gomez-Reino J, Carmona L, Descalzo M (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756–761PubMedCrossRefGoogle Scholar
  2. 2.
    Bean AG, Roach DR, Briscoe H et al (1999) Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection which is not compensated for by lymphotoxin. J Immunol 162:3504–3511PubMedGoogle Scholar
  3. 3.
    Flynn JL, Goldstein MM, Chan J et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561–572PubMedCrossRefGoogle Scholar
  4. 4.
    Keane J (2001) Tuberculosis associated with infliximab, a tumor necrosis factor–α-neutralizing agent. N Engl J Med 345:1098–1104PubMedCrossRefGoogle Scholar
  5. 5.
    Joven BE, Almodovar R, Galindo M, Mateo I, Pablos JL (2006) Does anti-tumour necrosis factor a treatment modify the tuberculin PPD response? Ann Rheum Dis 65:699PubMedCrossRefGoogle Scholar
  6. 6.
    Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159:15–21PubMedGoogle Scholar
  7. 7.
    Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360–1361PubMedCrossRefGoogle Scholar
  8. 8.
    Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H (2006) Infliximab does not suppress the tuberculin skin test (purified protein derivative. J Rheumatol 34:474–480Google Scholar
  9. 9.
    Fuchs-Polishuk I, Avnon LS, Abu shakra M (2007) Tuberculosis among patients treated with TNF-alpha blockers. Harefuah 146:212–218Google Scholar
  10. 10.
    Elkayam O, Balbir-gurman A, Lidgi M, Rahav G, Weiler-Ravel D (2007) Guidelines of the Israeli association of rheumatology for prevention of tuberculosis in patients treated with TNF-alpha blockers. Harefuah 146:235–237PubMedGoogle Scholar
  11. 11.
    Al Zahrani K, Al Jahdali H, Menzies D (2000) Does size matter? Utility of size of tuberculin reactions for the diagnosis of mycobacterial disease. Am J Respir Crit Care Med 162:1419–1422PubMedGoogle Scholar
  12. 12.
    Mow SW, Abreu-martin MT (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol and Hepatol 2:309–313CrossRefGoogle Scholar
  13. 13.
    Wang L, Turner MO, Elwood RK et al (2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurement. Thorax 57:804–809PubMedCrossRefGoogle Scholar
  14. 14.
    American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Resp Crit Care Med 161:S221–247Google Scholar
  15. 15.
    Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L (2001) Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 60:133–139PubMedCrossRefGoogle Scholar
  16. 16.
    Vanhoof J, Landewe S, Van Wijngaerden Geusens P (2003) High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 62:1241–1242PubMedCrossRefGoogle Scholar
  17. 17.
    Andersen P, Munk ME, Pollock JM, Doherty TM (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356:1099–1103PubMedCrossRefGoogle Scholar
  18. 18.
    Mazurek G, Jereb J, Lobue P, Iademerco M, Metchock B, Vernon A (2005) Guidelines or using the QuantiFERON-TB test for detecting Mycobacterium tuberculosis infection, United States. MMWR Morb mortal Wkly Recomm Rep 54(RR15):49–55Google Scholar
  19. 19.
    Ferrara G, Losi M, D’Amico R et al (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367:1328–1334PubMedCrossRefGoogle Scholar
  20. 20.
    Pratt A, Nicholl K, Kay L (2007) Use of QuantiFERON TB Gold test as part of a screening program in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle experience. Rheumatology 46:1035–1036PubMedCrossRefGoogle Scholar
  21. 21.
    Centers for Diseases Control and Prevention. Guidelines for Using the QuantiFERON®-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection. http:/www.cdc.gov/mmwr/preview/mmwrhtml/rr5202a2.htm

Copyright information

© Clinical Rheumatology 2008

Authors and Affiliations

  • Inbal Fuchs
    • 1
  • Lone Avnon
    • 2
  • Tamar Freud
    • 3
  • Mahmoud Abu-Shakra
    • 4
    • 5
  1. 1.Department of Family Medicine, Faculty of Health SciencesBen-Gurion UniversityBeer-ShevaIsrael
  2. 2.Pulmonology Unit, Soroka Medical Center and Faculty of Health SciencesBen-Gurion UniversityBeer-ShevaIsrael
  3. 3.Siaal Research Center for Family Medicine and Primary Care, Faculty of Health SciencesBen-Gurion UniversityBeer-ShevaIsrael
  4. 4.Rheumatic Diseases Unit, Soroka Medical Center and Faculty of Health SciencesBen-Gurion UniversityBeer-ShevaIsrael
  5. 5.Department of Medicine DSoroka University Medical CenterBeer-shevaIsrael

Personalised recommendations